BioAlliance Pharma, a developer of orphan oncology products and supportive care products, has entered a collaboration agreement with a leading vaccine company to develop a vaccine application of its Lauriad mucoadhesive technology. The terms of the agreement were not disclosed.   This research program aims to establish feasibility using Lauriad technology for vaccination, leading to an efficient needle-free administration of this mucoadhesive tablet containing a vaccine antigen.   “This collabor...